Another example is PDAC, where tumourigenesis is essentially driven by mutant KRAS. Targeting this oncogene only leads to tumour shrinkage, while sparing a fraction of cells with CSC features that have prominent expression of genes governing mitochondrial function and strong reliance on OXPHOS for cellular energetics. This evidence concerns the gene KRAS and neoplasm.